The content on this site is intended for healthcare professionals only
Prof Pierre Conte speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the management of patients with triple-positive breast cancer.
He explains that the prognosis of HR-positive patients is slightly better, compared to patients with HER-2 positive, HR-negative disease.
Prof Conte also the types of therapy available and the recent data from the APHINITY and ExteNET trials.
ASCO 2026: Breast cancer overview
Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
